Clinical trial
Bradykinin Receptor Antagonism During Cardiopulmonary Bypass
NCT00223704 · Vanderbilt University, Other · Completed
Key facts
| NCT number | NCT00223704 |
|---|---|
| Title | Bradykinin Receptor Antagonism During Cardiopulmonary Bypass |
| Official title | Bradykinin Receptor Antagonism During Cardiopulmonary Bypass |
| Acronym | BRAC |
| Lead sponsor | Vanderbilt University, Other |
| Status | Completed |
| Phase | Phase 2/Phase 3 |
| Study type | Interventional |
| Conditions | Cardiopulmonary Bypass, Inflammation, Fibrinolysis, Surgery |
| Intervention type | Drug |
| Interventions | HOE 140, Aminocaproic Acid, Placebo |
| Enrollment | 150 |
| Start date | May 1, 2006 |
| Primary completion | Jun 1, 2012 |
| Completion | Jun 1, 2012 |
| First posted | Sep 22, 2005 |
| Last update posted | Nov 25, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: